(Nb: Dulaglutude reports tomorrow)
Points of note?
1. In “good” renal function
2. As secondary outcome
3. Overarching outcome driven by reduction of persistent macroalbuminiuria
#ADA2019
![](https://pbs.twimg.com/media/D8kV2a6WwAAHrxe.jpg)
![](https://pbs.twimg.com/media/D8kXwKDXUAAZNgu.jpg)
![](https://pbs.twimg.com/media/D8kXwKNXYAAUxFO.jpg)
#ADA2019
![](https://pbs.twimg.com/media/D8ki1LpX4AAtrYv.jpg)
#ADA2019
![](https://pbs.twimg.com/media/D8kk6iQWwAcd-xB.jpg)
![](https://pbs.twimg.com/media/D8kk6iRXUAQbfa5.jpg)
It’s the type of patients and at what stage they are - regards kidney disease
Very beautifully explained!!
#ADA2019
![](https://pbs.twimg.com/media/D8klpOiWwAEUHxY.jpg)
#ADA2019
![](https://pbs.twimg.com/media/D8knyssX4AE6yEd.jpg)
![](https://pbs.twimg.com/media/D8knysrX4AAUiWX.jpg)